Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- School of Law hosts panel discussion on race, police use-of-force tactics
- Medicine’s Daniel Simon discusses significance of new heart technology
- Starting today, note second password field when using the VPN
- English’s T. Kenny Fountain to launch new book, ”Rhetoric in the Flesh,” at Jan. 29 event
- Examine how American Muslim book clubs are becoming feminist spaces at Jan. 28 discussion